We are Committed to being a Collaborative Platform for Innovative Biotech Companies from around the World.
Viva BioInnovator ("VBI") is the investment division of Viva Biotech Holdings (1873.HK). We are solely dedicated to the identification and success of early-stage, biotech start-ups for Viva’s incubation, equity-for-service, and investment platforms. Our commitment is to operate a collaborative platform for innovative biotech companies from around the world, and for anyone aiming to develop an idea with transformative or strong potential.
An Innovative Idea is All You Need
Our leading CRO platform is productive and efficient and it enables both quick and quality drug candidate discovery
Average time to invest: 2 months; Introductions for later-stage funding and financial advice
Business Partners Venture Advisors
Assistance in procuring internal or external resources
“Back-office” support (HR, Accounting, Procurement, BD, Financing, etc.)
We invest in some of the most innovative founders to build a unique portfolio covering a wide range of indications and drug types.
Read the most up to date information about us and our partners.
Viva Biotech 2020 Investor Day is rescheduled to December 8.
Bringing NanoSPR handheld detector and SARS-CoV-2 virus particle antigen detection kit to join the CIIE.
AR882 demonstrated a strong safety profile, favorable pharmacokinetics, pharmacodynamics, and efficacy outcome.
The collaboration will combine Biocytogen’s fully human antibody mouse platforms with Viva Biotech’s structure-based, integrated d...
This round of financing will be mainly used for the follow-up clinical research of AR882.
Quralis, a biotech company focused on the precise treatment of ALS and other neurological diseases, was included in the Fierce Bio...
